C35 (<i>C17orf37</i>) is a novel tumor biomarker abundantly expressed in breast cancer

Molecular Cancer Therapeutics - Tập 5 Số 11 - Trang 2919-2930 - 2006
Elizabeth E. Evans1,2,3, Alicia D. Henn2, Alan S. Jonason4, Mark Paris4, Linda Schiffhauer3, Melinda A. Borrello5,2, Ernest Smith4, Deepak M. Sahasrabudhe6,2,7, Maurice Zauderer5,2
11Vaccinex, Inc.;; 2The James P. Wilmot Cancer Center; and Departments of; 4Pathology, University of Rochester School of Medicine and Dentistry, Rochester, New York
22The James P. Wilmot Cancer Center; and Departments of
34Pathology, University of Rochester School of Medicine and Dentistry, Rochester, New York
41Vaccinex, Inc.;
51Vaccinex, Inc.;; 2The James P. Wilmot Cancer Center; and Departments of
61Vaccinex, Inc.;; 2The James P. Wilmot Cancer Center; and Departments of; 3Medicine and
73Medicine, and

Tóm tắt

Abstract Identification of shared tumor-specific targets is useful in developing broadly applicable therapies. In a study designed to identify genes up-regulated in breast cancer, a cDNA clone corresponding to a novel gene C35 (C17orf37) was selected by representational difference analysis of tumor and normal human mammary cell lines. Abundant expression of C35 transcript in tumors was confirmed by Northern blot and real-time PCR. The C35 gene is located on chromosome 17q12, 505 nucleotides from the 3′ end of the ERBB2 oncogene, the antigenic target for trastuzumab (HerceptinTM) therapy. The chromosomal arrangement of the genes encoding C35 and ERBB2 is tail to tail. An open reading frame encodes a 12-kDa protein of unknown function. Immunohistochemical analysis detected robust and frequent expression of C35 protein, including 32% of grade 1 and 66% of grades 2 and 3 infiltrating ductal carcinomas of the breast (in contrast to 20% overexpressing HER-2/neu), 38% of infiltrating lobular carcinoma (typically HER-2/neu negative), as well as tumors arising in other tissues. C35 was not detected in 38 different normal human tissues, except Leydig cells in the testes and trace levels in a small percentage of normal breast tissue samples. The distinct and favorable expression profile of C35 spanning early through late stages of disease, including high frequency of overexpression in various breast carcinoma, abundant expression in distant metastases, and either absence or low level expression in normal human tissues, warrants further investigation of the relevance of C35 as a biomarker and/or a target for development of broadly applicable cancer-specific therapies. [Mol Cancer Ther 2006;5(11):2919–30]

Từ khóa


Tài liệu tham khảo

American Cancer Society. Breast cancer facts and figures 2005–2006. Atlanta: American Cancer Society, Inc.; 2005.

Heo DS, Snyderman CH, Gollin SM, et al. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 1989;49:5167–75.

Band V, Sager R. Tumor progression in breast cancer. In: Rhim JS, Dritschilo A, editors. Neoplastic transformation in human cell culture. Totowa (NJ): The Human Press Inc.; 1991. p. 169–78.

Band V, Zajchowski D, Swisshelm K, et al. Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res 1990;50:7351–7.

Lisitsyn N, Wigler NM. Cloning the differences between two complex genomes. Science 1993;259:946–51.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Δ Δ C(T)) method. Methods 2001;4:402–8.

Chenchik A, Diachenko L, Moqadam F, Tarabykin V, Lukyanov S, Siebert PD. Full-length cDNA cloning and determination of mRNA 5′ and 3′ ends by amplification of adaptor-ligated cDNA. Biotechniques 1996;21:526–34.

Mitsui S, Okui A, Kominami K, Konishi E, Uemura H, Yamaguchi N. A Novel serine protease highly expressed in the pancreas is expressed in various kinds of cancer cells. FEBS J 2005;272:4911–23.

Wheeler DL, Church DM, Federhen S, et al. Database resources of the National Center for Biotechnology. Nucleic Acids Res 2003;31:28–33.

Tanaka S, Mori M, Akiyoshi T, et al. A novel variant of human GRB7 is associated with invasive esophageal carcinoma. J Clin Invest 1998;102:821–7.

Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer 2003;89:899–906.

Kryukov GV, Castellano S, Novoselov SV, et al. Characterization of mammalian selenoproteomes. Science 2003;300:1439–43.

Blom N, Gammeltoft S, Brunak S. Sequence- and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 1999;294:1351–62.

Hansen JE, Lund O, Engelbrecht J, et al. Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc:-polypeptide N-acetylgalactosaminyltransferase. Biochem J 1995;308:801–13.

Hansen JE, Lund O, Rapacki K, Brunak S. O-glycbase version 2.0 - A revised database of O-glycosylated proteins. Nucleic Acids Res 1997;25:78–282.

Hansen JE, Lund O, Tolstrup N, Gooley AA, Williams KL, Brunak S. NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility. Glycoconj J 1998;15:115–30.

Wu CH, Huang H, Arminski L, et al. The Protein Information Resource: an integrated public resource of functional annotation of proteins. Nucleic Acids Res 2002;30:35–7.

Fu H-W, Casey PJ. Enzymology and biology of CaaX protein prenylation. Recent Prog Horm Res 1999;54:315–43.

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 1987;235:177–82.

Rosenthal SI, Depowski PL, Sheehan CE, Ross JS. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem Mol Morphol 2002;10:40–6.

Body B. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy. Expert Opin Biol Ther 2002;2:577–84.

Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:R149–56.

Luoh S-H. Amplification and expression of genes from the 17q11∼q12 amplicon in breast cancer cells. Cancer Genet Cytogenet 2002;136:43–7.

Lassus H, Leminen A, Vayrynen A, et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 2004;95:416–7.

Czerwenka K, Lu Y, Heuss F. Amplification and expression of the c-erbB-2 oncogene in normal, hyperplastic, and malignant endometria. Int J Gynecol Pathol 1995;14:98–106.

Freier K, Joos S, Flechtenmacher C, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 2003;63:1179–82.

Takehana T, Kunitomo K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002;98:833–7.

Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37–45.

Stein D, Wu J, Fuqua SAW, et al. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J 1994;13:1331–40.

Ridolfi BL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 2000;13:866–73.

Maurer-Stroh S, Eisenhaber F. Refinement and prediction of protein prenylation motifs. Genome Biol 2005;6:R55. doi:10.1186/gb-2005–6-6-r55.

Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989;57:1167–77.

Jackson JH, Cochrane CG, Bourne JR, Solski PA, Buss JE, Der CJ. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci U S A 1990;87:3042–6.

Grande SM, Katz E, Crowley JE, Bernardini MS, Ross SR, Monroe JG. Cellular ITAM-containing proteins are oncoproteins in nonhematopoietic cells. Oncogene 2006;25:2748–57.

Garcia AM, Rowell C, Ackermann K, Kowalczyk JJ, Lewis MD. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J Biol Chem 1993;268:18415–8.

Casey PJ, Seabra MC. Protein prenylatransferases. J Biol Chem 1996;271:5289–92.

Karp JE, Lancet JE. Targeting the process of farynesylation for therapy of hematologic malignancies. Curr Mol Med 2005;5:643–52.

Kelland KR. Farnesyl transferase inhibitors in the treatment of breast cancer. Expert Opin Investig Drugs 2003;12:413–21.

Thông tin
Thông tin xuất bản

Molecular Cancer Therapeutics

Tập 5 Số 11

2919-2930

Thông tin tác giả